To enable SPORE investigators to rapidly develop new research opportunities which could translate into early benefits for breast cancer patients, and to allow for exploration of new techniques which may require substantial efforts but which are nevertheless not ready for full scale multi-year research funding, we have devoted considerable effort and resources to this SPORE Developmental Research Program. The Executive Committee, together with the advocate members and the Internal Advisory Board, selects proposals for funding as Developmental Projects, based on their scientific merit and relevance to SPORE translational goals. Through the funding of pilot projects, we broaden the scope of research, and allow exploration of high-risk ideas that have the potential for high yields in treatment, prevention, or basic biology of breast cancer. We also attract new investigators with a wide variety of special expertise to apply their expertise to problems and questions in breast cancer research, and we catalyze productive collaborations in which individual skills and approaches combine to create progress that no single investigator could achieve alone. It is important to point out that, although only $50,000 per year is requested from SPORE funds for this program, and Baylor College of Medicine is contributing an additional $50,000 per year in recognition of the value of this outreach effort to cancer research at Baylor. During the 26 years of funding since our first Breast SPORE award in 1992, we funded 106 developmental projects, contributing to 128 publications and providing essential preliminary data for 85 successful grant applications with several still pending. Two of the new full projects in this application derived in part from developmental projects to Drs. Chang and Westbrook. This mechanism complements the larger and longer- term regular research projects, offering a degree of flexibility which leads to enhanced productivity for the SPORE as a whole.

Public Health Relevance

For the fastest and most efficient progress against breast cancer, we need to draw the broadest possible range of ideas and approaches into the fight. SPORE developmental projects allow us to take on high risk research and attract new ideas, so that the most promising can earn support to become larger successful efforts either within the SPORE or with other major funding.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Niravath, Polly; Chen, Bingshu; Chapman, Judy-Anne W et al. (2018) Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer 18:78-87
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918

Showing the most recent 10 out of 28 publications